VERA THERAPEUTICS INC (VERA) Stock News
NASDAQ:VERA - Nasdaq - US92337R1014 - Common Stock - Currency: USD
VERA Latest News, Press Relases and Analysis
Which stocks are moving on Friday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Let's take a look at the stocks that are in motion in today's session.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Gapping stocks in Friday's session
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Discover the top movers in Friday's pre-market session.
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
The FDA granted Sarepta’s rAAVrh74 Viral Vector a Platform Technology Designation
The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy candidate SRP-9003 for limb-girdle muscular dystrophy type 2E/R4 (LGMD2E/R4), as a platform technology. Future approvals of treatments utilizing the same delivery technology might be accelerated by this designation. Phase III EMERGENE studies for SRP-9003, sometimes referred to […]
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on...
Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40
The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated.
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing...
Here are the top movers in Monday's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Which stocks are experiencing notable movement on Monday?
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Which stocks are gapping on Monday?
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
These stocks that are showing activity before the opening bell on Monday.
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46%...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee...
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation...